Suppr超能文献

由α-原肌球蛋白突变引起的家族性扩张型心肌病:肌节性扩张型心肌病的独特自然病史。

Familial dilated cardiomyopathy caused by an alpha-tropomyosin mutation: the distinctive natural history of sarcomeric dilated cardiomyopathy.

机构信息

Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.

出版信息

J Am Coll Cardiol. 2010 Jan 26;55(4):320-9. doi: 10.1016/j.jacc.2009.11.017.

Abstract

OBJECTIVES

We sought to further define the role of sarcomere mutations in dilated cardiomyopathy (DCM) and associated clinical phenotypes.

BACKGROUND

Mutations in several contractile proteins contribute to DCM, but definitive evidence for the roles of most sarcomere genes remains limited by the lack of robust genetic support.

METHODS

Direct sequencing of 6 sarcomere genes was performed on 334 probands with DCM. A novel D230N missense mutation in the gene encoding alpha-tropomyosin (TPM1) was identified. Functional assessment was performed by the use of an in vitro reconstituted sarcomere complex to evaluate ATPase regulation and Ca(2+) affinity as correlates of contractility.

RESULTS

TPM1 D230N segregated with DCM in 2 large unrelated families. This mutation altered an evolutionarily conserved residue and was absent in >1,000 control chromosomes. In vitro studies demonstrated major inhibitory effects on sarcomere function with reduced Ca(2+) sensitivity, maximum activation, and Ca(2+) affinity compared with wild-type TPM1. Clinical manifestations ranged from decompensated heart failure or sudden death in those presenting early in life to asymptomatic left ventricular dysfunction in those diagnosed during adulthood. Notably, several affected infants had remarkable improvement.

CONCLUSIONS

Genetic segregation in 2 unrelated families and functional analyses conclusively establish a pathogenic role for TPM1 mutations in DCM. In vitro results demonstrate contrasting effects of DCM and hypertrophic cardiomyopathy mutations in TPM1, suggesting that specific functional consequences shape cardiac remodeling. Along with previous reports, our data support a distinctive, age-dependent phenotype with sarcomere-associated DCM where presentation early in life is associated with severe, sometimes lethal, disease. These observations have implications for the management of familial DCM.

摘要

目的

我们旨在进一步明确肌节突变在扩张型心肌病(DCM)和相关临床表型中的作用。

背景

几种收缩蛋白的突变导致 DCM,但由于缺乏强有力的遗传支持,大多数肌节基因的确切作用仍存在局限性。

方法

对 334 名 DCM 先证者进行了 6 个肌节基因的直接测序。鉴定到编码α-原肌球蛋白(TPM1)的基因中的一个新的 D230N 错义突变。通过使用体外重组成肌节复合物来评估 ATP 酶调节和 Ca2+亲和力,作为收缩性的相关指标,进行功能评估。

结果

TPM1 D230N 在 2 个大型非相关家族中与 DCM 共分离。该突变改变了一个进化上保守的残基,并且在 >1000 个对照染色体中不存在。体外研究表明,与野生型 TPM1 相比,该突变对肌节功能具有主要的抑制作用,Ca2+敏感性、最大激活和 Ca2+亲和力降低。临床表现从生命早期出现失代偿性心力衰竭或猝死到成年期诊断出无症状左心室功能障碍不等。值得注意的是,一些受影响的婴儿有明显的改善。

结论

在 2 个不相关的家族中进行的遗传分离和功能分析,明确确立了 TPM1 突变在 DCM 中的致病性作用。体外结果表明,TPM1 中的 DCM 和肥厚型心肌病突变具有相反的作用,表明特定的功能后果塑造了心脏重塑。与之前的报道一致,我们的数据支持一种独特的、与年龄相关的表型,具有与肌节相关的 DCM,其早期发病与严重、有时致命的疾病相关。这些观察结果对家族性 DCM 的管理具有重要意义。

相似文献

3
Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy.
N Engl J Med. 2000 Dec 7;343(23):1688-96. doi: 10.1056/NEJM200012073432304.
5
Dilated cardiomyopathy mutations in thin-filament regulatory proteins reduce contractility, suppress systolic Ca, and activate NFAT and Akt signaling.
Am J Physiol Heart Circ Physiol. 2020 Aug 1;319(2):H306-H319. doi: 10.1152/ajpheart.00272.2020. Epub 2020 Jul 3.
6
Subtle abnormalities in contractile function are an early manifestation of sarcomere mutations in dilated cardiomyopathy.
Circ Cardiovasc Genet. 2012 Oct 1;5(5):503-10. doi: 10.1161/CIRCGENETICS.112.962761. Epub 2012 Sep 4.
7
A novel alpha-tropomyosin mutation associates with dilated and non-compaction cardiomyopathy and diminishes actin binding.
Biochim Biophys Acta. 2013 Apr;1833(4):833-9. doi: 10.1016/j.bbamcr.2012.11.003. Epub 2012 Nov 9.
8
[Mutations in genes for sarcomeric proteins].
Nihon Rinsho. 2000 Jan;58(1):117-22.
9
The structural basis of alpha-tropomyosin linked (Asp230Asn) familial dilated cardiomyopathy.
J Mol Cell Cardiol. 2017 Jul;108:127-137. doi: 10.1016/j.yjmcc.2017.06.001. Epub 2017 Jun 7.

引用本文的文献

2
Dilated Cardiomyopathy: A Genetic Journey from Past to Future.
Int J Mol Sci. 2024 Oct 25;25(21):11460. doi: 10.3390/ijms252111460.
3
In silico and in vitro models reveal the molecular mechanisms of hypocontractility caused by M8R.
Front Physiol. 2024 Aug 30;15:1452509. doi: 10.3389/fphys.2024.1452509. eCollection 2024.
7
Sex Differences in Heart Failure: What Do We Know?
J Cardiovasc Dev Dis. 2023 Jun 29;10(7):277. doi: 10.3390/jcdd10070277.
8
Cardiovascular Magnetic Resonance Imaging in Familial Dilated Cardiomyopathy.
Medicina (Kaunas). 2023 Feb 23;59(3):439. doi: 10.3390/medicina59030439.
9
Prognostic Prediction of Genotype vs Phenotype in Genetic Cardiomyopathies.
J Am Coll Cardiol. 2022 Nov 22;80(21):1981-1994. doi: 10.1016/j.jacc.2022.08.804.

本文引用的文献

1
Genetic evaluation of cardiomyopathy--a Heart Failure Society of America practice guideline.
J Card Fail. 2009 Mar;15(2):83-97. doi: 10.1016/j.cardfail.2009.01.006.
2
Long-term outcome and risk stratification in dilated cardiolaminopathies.
J Am Coll Cardiol. 2008 Oct 7;52(15):1250-60. doi: 10.1016/j.jacc.2008.06.044.
6
Hypertrophic and dilated cardiomyopathy mutations differentially affect the molecular force generation of mouse alpha-cardiac myosin in the laser trap assay.
Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H284-91. doi: 10.1152/ajpheart.00128.2007. Epub 2007 Mar 9.
7
Incidence, causes, and outcomes of dilated cardiomyopathy in children.
JAMA. 2006 Oct 18;296(15):1867-76. doi: 10.1001/jama.296.15.1867.
8
A contemporary approach to hypertrophic cardiomyopathy.
Circulation. 2006 Jun 20;113(24):e858-62. doi: 10.1161/CIRCULATIONAHA.105.591982.
10
Echocardiographic evaluation in asymptomatic relatives of patients with dilated cardiomyopathy reveals preclinical disease.
Ann Intern Med. 2005 Jul 19;143(2):108-15. doi: 10.7326/0003-4819-143-2-200507190-00009.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验